Allspring Global Investments Holdings LLC Purchases 5,007 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Allspring Global Investments Holdings LLC lifted its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 3.5% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 148,488 shares of the biopharmaceutical company’s stock after purchasing an additional 5,007 shares during the quarter. Allspring Global Investments Holdings LLC owned 0.13% of Catalyst Pharmaceuticals worth $2,300,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. GAMMA Investing LLC lifted its holdings in Catalyst Pharmaceuticals by 72.9% during the first quarter. GAMMA Investing LLC now owns 1,942 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 819 shares in the last quarter. CWM LLC raised its position in shares of Catalyst Pharmaceuticals by 686.5% during the second quarter. CWM LLC now owns 4,066 shares of the biopharmaceutical company’s stock worth $63,000 after purchasing an additional 3,549 shares during the period. Headlands Technologies LLC bought a new position in shares of Catalyst Pharmaceuticals during the 1st quarter valued at about $154,000. Ameritas Investment Partners Inc. grew its position in shares of Catalyst Pharmaceuticals by 6.9% in the 1st quarter. Ameritas Investment Partners Inc. now owns 11,116 shares of the biopharmaceutical company’s stock valued at $177,000 after purchasing an additional 720 shares during the period. Finally, Virtu Financial LLC bought a new stake in Catalyst Pharmaceuticals during the 1st quarter worth approximately $191,000. Institutional investors and hedge funds own 79.22% of the company’s stock.

Insider Buying and Selling

In other Catalyst Pharmaceuticals news, insider Carmen Jeffrey Del sold 7,541 shares of the stock in a transaction on Friday, June 7th. The shares were sold at an average price of $16.07, for a total value of $121,183.87. Following the completion of the sale, the insider now owns 18,427 shares in the company, valued at $296,121.89. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other Catalyst Pharmaceuticals news, insider Carmen Jeffrey Del sold 7,541 shares of the business’s stock in a transaction that occurred on Friday, June 7th. The stock was sold at an average price of $16.07, for a total transaction of $121,183.87. Following the transaction, the insider now owns 18,427 shares of the company’s stock, valued at $296,121.89. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Steve Miller sold 150,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $20.35, for a total value of $3,052,500.00. Following the completion of the sale, the insider now owns 675,124 shares in the company, valued at approximately $13,738,773.40. The disclosure for this sale can be found here. Over the last three months, insiders have sold 288,599 shares of company stock worth $5,432,172. Insiders own 11.00% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have weighed in on CPRX. StockNews.com raised shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 9th. Citigroup upped their target price on shares of Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. HC Wainwright increased their target price on Catalyst Pharmaceuticals from $26.00 to $30.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Oppenheimer restated an “outperform” rating and issued a $29.00 price target on shares of Catalyst Pharmaceuticals in a report on Thursday, June 6th. Finally, Truist Financial increased their price objective on Catalyst Pharmaceuticals from $25.00 to $30.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Catalyst Pharmaceuticals has an average rating of “Buy” and a consensus price target of $29.50.

Catalyst Pharmaceuticals Stock Performance

NASDAQ:CPRX opened at $20.25 on Tuesday. Catalyst Pharmaceuticals, Inc. has a 52-week low of $11.55 and a 52-week high of $20.87. The company has a market cap of $2.40 billion, a P/E ratio of 37.50, a P/E/G ratio of 3.30 and a beta of 0.70. The stock’s 50-day simple moving average is $17.62 and its 200 day simple moving average is $16.31.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last posted its quarterly earnings results on Wednesday, August 7th. The biopharmaceutical company reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.39 by $0.13. Catalyst Pharmaceuticals had a return on equity of 27.77% and a net margin of 15.69%. The firm had revenue of $122.71 million for the quarter, compared to analyst estimates of $111.76 million. As a group, equities analysts predict that Catalyst Pharmaceuticals, Inc. will post 1.82 earnings per share for the current fiscal year.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.